Genentech inc. - Articles - Page 7

Peptidream, Genentech ink $1B deal for peptide-radioisotope drug conjugates

Sep. 26, 2023

Peptidream Inc. and Genentech Inc., a Roche Holding company, signed a deal worth up to $1 billion to discover and develop macrocyclic peptide-radioisotope (peptide-RI) drug conjugates. Peptidream, of Kawasaki, Japan, will use its peptide discovery platform system technology to discover, optimize and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech. Genentech will pay Peptidream an up-front payment of $40 million and up to $1 billion in potential development, regulatory, and commercial-based milestones. In addition, Peptidream is eligible to receive tiered royalties on net sales (ex-Japan) of any products arising from the collaboration.

Drug Design, Drug Delivery & Technologies

Orionis Biosciences collaborates with Genentech to discover molecular glues

Sep. 21, 2023

Orionis Biosciences BV has established a multiyear collaboration with Genentech Inc., a member of the Roche Group, to discover novel small-molecule molecular glues for targets in major disease areas, including oncology and neurodegeneration.

Lack of enablement takes down another genus claim

Sep. 20, 2023

The impact of the U.S. Supreme Court’s full scope enablement ruling in Amgen Inc. v. Sanofi SA is reverberating through other genus patent challenges.

Peptidream, Genentech ink $1B deal for peptide-radioisotope drug conjugates

Sep. 20, 2023

By Tamra Sami

Peptidream Inc. and Genentech Inc., a Roche Holding company, signed a deal worth up to $1 billion to discover and develop macrocyclic peptide-radioisotope (peptide-RI) drug conjugates. Peptidream, of Kawasaki, Japan, will use its peptide discovery platform system technology to discover, optimize and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech. Genentech will pay Peptidream an up-front payment of $40 million and up to $1 billion in potential development, regulatory, and commercial-based milestones. In addition, Peptidream is eligible to receive tiered royalties on net sales (ex-Japan) of any products arising from the collaboration.

3D rendering conceptualizing theranostics

Drug Design, Drug Delivery & Technologies

Peptidream collaborates with Genentech on discovery and development of peptide-radioisotope drug conjugates

Sep. 20, 2023

Peptidream Inc. has entered into a new multitarget collaboration and license agreement with Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

Cancer

Discovery of selective CDK2 inhibitors with potent antitumor activity

Sep. 5, 2023

Researchers from Genentech Inc. have reported the discovery of new cyclin-dependent kinase 2 (CDK2) inhibitors as potential anticancer agents.

Alecensa sends a positive phase III message to Genentech in early NSCLC

Sep. 1, 2023

By Randy Osborne

Roche Holding AG’s Genentech subsidiary has broken new ground with a victory in phase III testing of the oral, anaplastic lymphoma kinase (ALK) inhibitor Alecensa (alectinib) in early stage, ALK-positive non-small-cell lung cancer (NSCLC). The drug, well known to doctors in the advanced setting, was compared with platinum-based chemotherapy and met its primary endpoint of disease-free survival at a prespecified interim analysis.

Respiratory

GDC-6599, a new TRPA1 antagonist with a promising preclinical PK and toxicity profile

Aug. 30, 2023

Researchers from Genentech Inc. presented preclinical data for the novel transient receptor potential ankyrin 1 (TRPA1) antagonist GDC-6599, currently in phase II development for respiratory indications.

Neurology/Psychiatric

Convelo and Genentech patent new EBP inhibitors

June 26, 2023

Convelo Therapeutics Inc. and Genentech Inc. have disclosed 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, optic neuritis, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.

Cancer

Arvinas and Genentech discover new SMARCA2 degradation inducers

June 23, 2023

Arvinas Operations Inc. and Genentech Inc. have described proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) targeting moiety through a linker reported to be useful for the treatment of cancer, including non-small-cell lung cancer.